Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized
by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally
accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also
given the paucity of randomized controlled study and high-quality data. However, the literature on the
effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical
characteristics, histopathologic features, and management of pyoderma gangrenosum as well as
Sweet’s syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome.
The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17,
and IL-23 are discussed in detail.